Skip to main content
Have a personal or library account? Click to login
Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer Cover

Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer

Open Access
|Oct 2024

Figures & Tables

Table 1:

Patients’ characteristics. PSA pre-RT: PSA values detected at the time of PSMA-PET before the start of RT. PSA post-RT: PSA values detected at the first follow-up check 3 months after the end of RT. PSADT: PSA doubling time. BF: biochemical failure at the first follow-up check 3 months after the end of RT.

Number of patients70
Age59–84 yearsMean 71.1 years (SD 5.1)
PSA pre-RT0.2–5.69 ng/mLMean 0.81 ng/mL (SD 0.91)
PSA post-RT0.01–1.55 ng/mLMean 0.11 ng/mL (SD 0.24)
PSADT3–87.2 monthsMean 14 months (SD 16)
BF2/70 patients
Follow-up6–60 monthsMean 24 months
Figure 1:

Flowchart of the study.

Figure 2:

PSA value distribution divided by PET status: the green bars represent patients with negative PET; the red bars represent patients with positive PET.

Table 2:

Results of PSA trend (increase or decrease) post radiotherapy in function of the PET status for whole patient group. SRT: salvage radiotherapy.

Whole patient groupPSA trend post SRT
DecreasesIncreases
PET statusPositive532
Negative150
Table 3:

Results of PSA trend post radiotherapy in function of the PET status for patients irradiated on the prostatic fossa after surgery. SRT: salvage radiotherapy.

PSA trend post SRT
DecreasesIncreases
GroupGroup 1390
Group 2150
Table 4:

Results of PSA trend post radiotherapy in function of the PET status for patients irradiated on the prostatic fossa after surgery with PSA ≤ 1 ng/mL. SRT: salvage radiotherapy.

Group 1+2 with PSA ≤ 1 ng/mLPSA trend post SRT
DecreasesIncreases
Group 1250
Group 2150
Table 5:

Sensitivity and accuracy calculated for the whole group and for the subgroups 1+2 and 1+2 with PSA ≤ 1 ng/mL.

SensibilityAccuracy
Whole patient group78%76%
Group 1+272%72%
Group 1+2 with PSA ≤ 1 ng/mL62%62%
DOI: https://doi.org/10.2478/fco-2023-0034 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Page range: 53 - 60
Submitted on: Feb 11, 2024
Accepted on: Sep 4, 2024
Published on: Oct 17, 2024
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services

© 2024 Riccardo Vigna-Taglianti, Alberto Boriano, Stefania Martini, Francesco Olivero, Salvatore Solla, Lavinia Spinelli, Luca Gianello, Simona Peano, Anna Maria Merlotti, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.